Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Ahmad-Samer Al-Homsi, Sebastien Anguille, Dries Deeren, Taiga Nishihori, Nathalie Meuleman, Maher Abdul-Hay, Gareth J. Morgan, Jason Brayer, Nathalie Braun, Caroline Lonez, Marie-Sophie Dheur, Erik Alcantar-Orozco, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2021-147738

Published: 2021

Journal Articles

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Jacques Azzi, MD, Frank Cirrone, PharmD, Maher Abdul Hay, MD, David Kaminetzky, MD, Kenneth B. Hymes, MD, Maxim Kreditor, MD, Ahmad-Samer Al-Homsi, MD, Michael L. Grossbard, MD, Catherine Diefenbach, MD, Tibor Moskovits, MD, Shella Saint Fleur-Lominy, MD PhD, Bruce G. Raphael, MD, Raoul Tibes, MD PhD

Blood (2018) 132 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2018-99-117314

Published: 2018

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Epstein-Barr Virus (EBV) Associated Post-Transplantation Lymphoproliferative Disorder Confined to the Central Nervous System Despite Negative Serum EBV PCR Following Rituxmab Administration.

Cannon Milani, MD, Rami Abumasmah, Ahmad-Samer Al-Homsi, MD

Blood (2009) 114 (22): 4303.

https://doi.org/10.1182/blood.V114.22.4303.4303

Published: 2009

Journal Articles

Phase I Trial of HuLuc63 in Multiple Myeloma.

William Bensinger, Jeffrey Zonder, Seema Singhal, Ann Mohrbacher, Robert M. Dean, Frits van Rhee, Ahmad-Samer Al-Homsi, Nikhil C. Munshi, Edward R. Conner, Mohamad A. Hussein

Blood (2007) 110 (11): 1180.

https://doi.org/10.1182/blood.V110.11.1180.1180

Published: 2007

Journal Articles

Cost-Consequences of Fondaparinux Use for Treatment of Heparin-Induced Thrombocytopenia.

Abir O. Kanaan, PharmD, Jennifer L. Donovan, PharmD, Paul P. Belliveau, PharmD, Tara Roy, NP, Ahmad-Samer Al-Homsi, MD

Blood (2006) 108 (11): 4126.

https://doi.org/10.1182/blood.V108.11.4126.4126

Published: 2006

Journal Articles

Venous Thromboembolism Prophylaxis in High Risk Medically Ill Patients; a Meta Analysis.

Abir O. Kanaan, PharmD, Jennifer L. Donovan, PharmD, Matthew A. Silva, PharmD, Tara Roy, NP, Ahmad-Samer Al Homsi, MD

Blood (2006) 108 (11): 875.

https://doi.org/10.1182/blood.V108.11.875.875

Published: 2006

NARROW

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Epstein-Barr Virus (EBV) Associated Post-Transplantation Lymphoproliferative Disorder Confined to the Central Nervous System Despite Negative Serum EBV PCR Following Rituxmab Administration.

Phase I Trial of HuLuc63 in Multiple Myeloma.

Cost-Consequences of Fondaparinux Use for Treatment of Heparin-Induced Thrombocytopenia.

Venous Thromboembolism Prophylaxis in High Risk Medically Ill Patients; a Meta Analysis.

Email alerts

ASH Publications

American Society of Hematology

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Epstein-Barr Virus (EBV) Associated Post-Transplantation Lymphoproliferative Disorder Confined to the Central Nervous System Despite Negative Serum EBV PCR Following Rituxmab Administration.

Phase I Trial of HuLuc63 in Multiple Myeloma.

Cost-Consequences of Fondaparinux Use for Treatment of Heparin-Induced Thrombocytopenia.

Venous Thromboembolism Prophylaxis in High Risk Medically Ill Patients; a Meta Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only